VCNX - Vaccinex, Inc. Debt to Book Capitalization Ratio

The percentage of debt in the balance sheet capital on the GURU.Markets system chart demonstrates leverage dynamics, where 0.00 reflects the latest value of the metric. Vaccinex, Inc. (VCNX) business efficiency depends on the neuroprotective properties of pepinemab in Alzheimer's therapy. Experienced management is developing platforms to combat oncology. Currently, the company is cutting costs and seeking partners for antibody development.

VCNX Vaccinex, Inc.: Debt to Book Capitalization Ratio in the range 07/04/2022 - 12/28/2024

Summary analytical data breakdowns for Vaccinex Inc. (VCNX)

- price and consensus price forecast:

Stock Price Vaccinex, Inc.|VCNX - Consensus Target

- market capitalization data:

Market Value Vaccinex Inc|VCNX - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Vaccinex|VCNX - Company Book Value|Market Value to Book Value Ratio vaccinex.com|VCNX - Company Assets

- debt and liquidity data:

Total Debt to Capital Vaccinex, Inc.|VCNX - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Vaccinex, Inc|VCNX - Company Cumulative Debt|Debt to Book Value Vaccinex Inc

Analysis of all company metrics:VCNX, Vaccinex, Inc.

Searching for fundamentally resilient assets requires eliminating cognitive biases when assessing leverage. This indicator compares total liabilities to the book value of equity, measuring the level of financial risk and potential return on equity. For Vaccinex, Inc. (VCNX), with its proprietary SEMA4D platform and R&D contracts, such a metric reflects the financing efficiency of its development projects. A decrease in this value confirms the reliability of the balance sheet structure. By analyzing the dynamics of the debt-to-book capital ratio, an investor determines the objective stability of Vaccinex, Inc. (VCNX).

Competitors of Vaccinex, Inc.